TABLE 3.

VZV-specific antibody titer by age stratum and vaccination group (per protocol population)

Age group (yr)Time pointRefrigerated formulation group (n = 182)Frozen formulation group (n = 185)
No. of subjectsGeometric mean endpoint titera (95% CI)Median (range) geometric mean endpoint titerGeometric mean fold rise from day 1 (95% CI)No. of subjectsGeometric mean endpoint titer (95% CI)Median (range) geometric mean endpoint titerGeometric mean fold rise from day 1 (95% CI)
50-59Day 165244 (179, 331)214 (21, 8,606)68234 (181, 302)216 (26, 2,166)
Wk 462731 (542, 987)779 (43, 21,284)66763 (553, 1,051)976 (44, 25,748)
Wk 4613.1 (2.3, 4.2)653.3 (2.5, 4.3)
≥60Day 1115302 (242, 377)252 (24, 19,371)116328 (264, 406)268 (35, 28,546)
Wk 4114710 (580, 870)773 (68, 38,606)112897 (719, 1,121)988 (82, 36,807)
Wk 41132.3 (1.9, 2.8)1122.7 (2.2, 3.3)
CombinedDay 1180279 (234, 334)244 (21, 19,371)184289 (245, 341)256 (26, 28,546)
Wk 4176717 (607, 848)773 (43, 38,606)178845 (704, 1,014)979 (44, 36,807)
Wk 41742.6 (2.2, 3.0)1772.9 (2.4, 3.4)
  • a The endpoint titers are expressed as gpELISA units/ml.